Expires: January 31, 2021  

Presentation

 

Overview

This webinar will discuss the diagnosis, pathological understanding, and current best treatment options for necrotizing autoimmune myopathy.  

Presenters

Christopher Klein, M.D. Professor of Neurology Mayo Clinic College of Medicine and Science Division of Clinical Biochemistry and Clinical Genomics Mayo Clinic, Rochester, Minnesota      

Learning Objectives

Upon completion of this activity, participants should be able to:

• Discuss the clinical presentations of necrotizing autoimmune myopathy, also known as immune-mediated necrotizing myopathy.
• Recognize the latest understanding of the autoimmune pathogenesis and therapeutic interventions.
• Identify the current test platforms available to make the diagnosis and their clinical sensitivity and specificity.

 

Intended Audience

This webinar is designed for any provider who sees patients with a neurologic disease (e.g., neurologists, psychiatrists, and primary care physicians, including internists and family care practitioners) as well as pathologists, laboratory directors, and laboratory sendout coordinators.  

Credit

The following types of credit are offered for this event: ASCLS P.A.C.E.^® State of California State of Florida To obtain credit:

1. Watch the video.
2. Complete the posttest and evaluation that launches immediately following the video.
3. Generate and print your certificate(s).

  Level of instruction for this program is Advanced.

ASCLS P.A.C.E.^®

Mayo Clinic Laboratories is approved as a provider of continuing education programs in the Clinical Laboratory Sciences by the ASCLS P.A.C.E.^® program. This program has been approved for a maximum of 1.0 P.A.C.E.^® contact hour.

State of California

Mayo Clinic Laboratories is approved as a Continuing Education Accrediting Agency for Clinical Laboratory Sciences for State of California. This program has been approved for 1.0 contact hour.

State of Florida

Mayo Clinic Laboratories is approved as a Continuing Education Accrediting Agency for the clinical laboratory sciences for the State of Florida. Florida Board of Clinical Laboratory Personnel has designated this program for General credit. This program has been approved for 1.0 contact hour.  

Faculty Disclosure

Course director(s), planning committee, faculty, and all others who are in a position to control the content of this educational activity are required to disclose all relevant financial relationships with any commercial interest related to the subject matter of the educational activity. Safeguards against commercial bias have been put in place. Faculty members also will disclose any off-label and/or investigational use of pharmaceuticals or instruments discussed in their presentations. Disclosure of this information will be published in course materials so those participants in the activity may formulate their own judgments regarding the presentations.